Daiichi Sankyo reports top-line results from Phase III trials of mirogabalin

Japanese pharmaceutical firm Daiichi Sankyo has reported top-line results from its Phase III NEUCOURSE and ALDAY clinical trials of mirogabalin to treat post-herpetic neuralgia and fibromyalgia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news